First anticancer immune cells with modulated cell memory.
TezR-modified donor leukocytes with unlocked novel mechanisms of tumor eradication
NOT
CAR-T
CAR-NK
Gene-edited
TILs
Novel
Mechanisms
of tumor
eradication.
Nothing
known before
Meet the
Leukocyte-Tells
(SL-28)
A First-in-Class Cell Therapy
Leukocyte-Tells (SL-28) are the first allogeneic, non-genetically modified, donor-derived immune cells engineered through cellular memory modulation via the Universal Receptive System. This novel approach unlocks anticancer mechanisms that were previously inaccessible.
Clinical Development
Through our pioneering expertise, we are harnessing the therapeutic potential of donor-derived leukocytes to fight advanced solid tumors. Our clinical development and expanded access programs are designed to deliver these transformative therapies quickly to patients with advanced cancers who have no further treatment options.
How it WorksFrom immune cellsto Powerful Therapy
Leukocyte-Tells are created from immune cells donated by healthy individuals. Using our first-in-class technology, we modulate Cell Memory through the Universal Receptive System, transforming ordinary immune cells into Leukocyte-Tells with powerful anticancer activity.
Analyses
Extensive analyses show that hundreds of genes are upregulated in Leukocyte-Tells, activating key anticancer pathways such as:
Immune
cell signaling
Immune
cell migration
Endocytosis
& phagocytosis
Energy
metabolism
Leukocyte-Tells also generate unique anticancer peptides and metabolites, further enhancing their therapeutic effect.
At Second Life Therapeutics,
Therapeutics,
we didn’t need to make a cartoon
make a cartoon
to illustrate the mechanism
the mechanism
of action of Leukocyte-Tells (SL28).
Leukocyte-Tells
(SL28).
Our science is validated sufficiently, and we have clinical proof that Leukocyte-Tells (SL-28) works. Here is IRL imagery to show it.
01
Donor derived leukocyte
(CD8+ T cells, CD15+)
02
Leukocyte-Tells
(SL-28)
03
Cancer cells
04
Leukocyte-Tells (SL-28)
result in tumor destruction
At Second Life Therapeutics, we see science as a form of art. So instead of another boring diagram, we drew you a story of how Leukocyte-Tells (SL-28) actually work.
01
Donor derived leukocyte (CD8+ T cells, CD15+)
Proprietary activation through the Universal Receptive System to generate Leukocyte-Tells (SL-28)
02
Leukocyte-Tells (SL-28)
03
Leukocyte-Tells (SL-28) result in tumor destruction
How SL-28 Works in Patients
Once injected, Leukocyte-Tells actively seek out and destroy tumor cells. Designed to be cancer-agnostic, SL-28 to targets:
-
Primary tumors
-
Metastatic sites
-
Individual circulating cancer cells
This makes
SL-28 a truly universal
universal
approach to cancer therapy
cancer therapy
Second Life Therapeutics is part of Second Life Group, a collective of biotech companies addressing medicine's most critical, unmet needs, with science and technology developed in close collaboration with Tetz Laboratories in New York. Together, we are pioneering a new generation of therapies that bring hope to patients facing the most challenging cancers.
How SL-28 Cell
Therapy is Different
First-in-Class Innovation
SL-28 is a breakthrough cell therapy designed to overcome the limitations of current treatments for advanced solid tumors.
Unique Mechanism
Our proprietary platform modulates immune cell activity through the Universal Receptive System and Cell Memory, unlocking anticancer pathways never activated in CAR-T, TIL, or other existing therapies.
Through TezR modulation, SL-28 reprograms donor immune cells to generate durable and adaptable responses against some of the most difficult-to-treat cancers.
Ready When Patients Need It
Unlike therapies that require months of manufacturing, SL-28 provides off-the-shelf Leukocyte-Tells allogeneic immune cells ready for immediate use. Patients with urgent needs can begin treatment without delays.
SL-28 is an off-the-shelf
anticancer cell therapy
designed to help patients
with resistant cancers,
including those previously
considered “untreatable“
SL-28 is an
off-the-shelf
anticancer cell
therapy designed
to help patients
with resistant
cancers, including
those previously
considered
“untreatable“
-
Healthy donors
Leukapheresis
-
Isolate white blood cells (WBC)
-
WBCs ex vivo through activated by targeting novel TezR receptors
Increased anticancer activity
Reduced HLA reactivity
-
SL-28 Immediate Infusion for many patients
-
Scalable Allogeneic WBC Manufacturing
Fill finish of 1000+ doses/batch
Problems we solve:
advanced solid tumors
tumors
The Challenge of Advanced Solid Tumors
Advanced solid tumors remain among the most difficult cancers to treat. They are often diagnosed late, after spreading beyond the original site, and frequently prove resistant to standard therapies.
Despite decades of progress in surgery, chemotherapy, radiotherapy, and targeted treatments, both 1-year and 5-year survival rates remain unacceptably low, reflecting the aggressive nature of these diseases and the lack of effective therapies. Patients face limited treatment options and rapid disease progression, underscoring the urgent need for more effective therapies.
SL-28 is a different kind of immune cell adoptive therapy, and unlike CAR T or TILs, has proven to be effective in treating a broad range of advanced solid tumor cancers, even in cases with a heavy tumor burden.
Our Approach:
Leukocyte-Tells (SL-28)
(SL-28)
Second Life Therapeutics has developed Leukocyte-Tells (SL-28), a universal cell therapy designed to treat a broad range of advanced solid tumors.
Through our expanded access program, SL-28 has already shown encouraging efficacy in patients with Stage IV cancers.
Disclaimer: Leukocyte-Tells (SL-28) is an investigational drug that has not been approved by any regulatory authority. Its safety and effectiveness have not yet been fully established.
Pipeline
Unlike traditional immunotherapies, SL-28 leverages TezR-modified donor leukocytes to unlock novel mechanisms of tumor eradication. With strong preclinical data, compassionate use human data, and a defined regulatory strategy, we are moving rapidly toward clinical translation.
| Drug candidate | Indication | Discovery | Pre-clinical | Phase I/II | Phase IIb/III |
|---|---|---|---|---|---|
| SL-28 |
Head and NeckOral cavityThyroid cancer
|
|
|||
| SL-28 |
ThoracicSmall-cell lung cancerNon-small cell lung cancerMesotheliomaEsophageal cancer
|
|
|||
| SL-28 |
GastrointestinalGastric cancerLiver cancerColorectal cancerPancreatic cancer
|
|
|||
| SL-28 |
GenitourinaryBladder cancerRenal cell carcinomaProstate cancer
|
|
|||
| SL-28 |
GynecologicOvarian cancerEndometrial cancer
|
|
|||
| SL-28 |
Breast and SkinBreast cancerMelanoma
|
|
|||
Publications
Regulating white blood cell activity through the novel universal receptive system
The universal receptive system: a novel regulator of antimicrobial and anticancer compound production by white blood cells
Dramatic Clinical Response to a Novel Form of Cell Therapy SL-28 in a Patient with Prostate Cancer and Bone Metastasis: A Case Report
Partial response in a patient with skeletal and hepatic metastases following resected pancreatic cancer to the novel cell therapy SL-28: a case report
Novel Cell Receptor System of Eukaryotes Formed by Previously Unknown Nucleic Acid-Based Receptors
